Literature DB >> 18309961

Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy.

Laurence Gamelin, Michèle Boisdron-Celle, Alain Morel, Anne Lise Poirier, Virginie Berger, Erick Gamelin, Christophe Tournigand, Aimery de Gramont.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18309961     DOI： 10.1200/JCO.2007.15.3767

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  28 in total

1.  Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

Authors:  Axel Grothey; Daniel A Nikcevich; Jeff A Sloan; John W Kugler; Peter T Silberstein; Todor Dentchev; Donald B Wender; Paul J Novotny; Umesh Chitaley; Steven R Alberts; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  Activation of KCNQ Channels Prevents Paclitaxel-Induced Peripheral Neuropathy and Associated Neuropathic Pain.

Authors:  Lin Li; Jinxiu Li; Yan Zuo; Danny Dang; Jeffrey A Frost; Qing Yang
Journal:  J Pain       Date:  2018-11-22       Impact factor: 5.820

3.  Cetuximab-induced hypomagnesaemia aggravates peripheral sensory neurotoxicity caused by oxaliplatin.

Authors:  Toru Kono; Machiko Satomi; Toshiyuki Asama; Yoshiaki Ebisawa; Naoyuki Chisato; Manabu Suno; Hidenori Karasaki; Hiroyuki Furukawa; Kazuo Matsubara
Journal:  J Gastrointest Oncol       Date:  2010-12

4.  Chemotherapy-Induced Peripheral Neuropathy in Pediatric Cancer Patients.

Authors:  Rhonda J Moore; Hunter Groninger
Journal:  Cureus       Date:  2013-06-14

5.  The search for treatments to reduce chemotherapy-induced peripheral neuropathy.

Authors:  Deirdre R Pachman; Charles L Loprinzi; Axel Grothey; Lauren E Ta
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

6.  Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.

Authors:  Eiji Oki; Yasunori Emi; Hiroshi Kojima; Jun Higashijima; Takeshi Kato; Yasuhiro Miyake; Masanori Kon; Yutaka Ogata; Kenichi Takahashi; Hideyuki Ishida; Hiroshi Saeki; Yoshihisa Sakaguchi; Takeharu Yamanaka; Toru Kono; Naohiro Tomita; Hideo Baba; Ken Shirabe; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2015-01-28       Impact factor: 3.402

7.  Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.

Authors:  H S Hochster; A Grothey; L Hart; K Rowland; R Ansari; S Alberts; N Chowhan; R K Ramanathan; M Keaton; J D Hainsworth; B H Childs
Journal:  Ann Oncol       Date:  2014-03-07       Impact factor: 32.976

8.  Transient bilateral abducens neuropathy with post-tetanic facilitation and acute hypokalemia associated with oxaliplatin: a case report.

Authors:  Min-Han Tan; Wen Yee Chay; Jia Hui Ng; Bin Tean Teh; Lita Chew
Journal:  J Med Case Rep       Date:  2010-02-02

9.  Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).

Authors:  Charles L Loprinzi; Rui Qin; Shaker R Dakhil; Louis Fehrenbacher; Kathleen A Flynn; Pamela Atherton; Drew Seisler; Rubina Qamar; Grant C Lewis; Axel Grothey
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

Review 10.  Update on medication-induced peripheral neuropathy.

Authors:  Louis H Weimer; Noor Sachdev
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.